Clifford Samuel advises companies and NGOs on access to and distribution of life-saving medicines in low- and middle-income countries. He has 30+ years of experience in the biopharmaceutical industry, with more than two decades at Gilead Sciences (1996-2020) in leadership roles, culminating as SVP responsible for more than 140 countries. Clifford spearheaded Gilead’s entry into voluntary licensing agreements with companies in India, Pakistan, and South Africa, creating competitive markets for generic HIV, hepatitis B and C, and COVID-19 treatments. From 2022 to 2023, Clifford was a fellow at Harvard University's Berkman Klein Center exploring voluntary licensing and access to medicines. He is a fellow at the American Institute for Medical and Biological Engineering, is on the boards of Antiva Biosciences and MTV's Staying Alive Foundation, and is an advisor to Siolta Therapeutics, Pardes Biosciences, and Karkinos Healthcare (India). A graduate of the New Jersey Institute of Technology (NJIT) with a BS in Mechanical Engineering, he received an Honorary PhD from NJIT, and is on the Industrial Advisory Board for NJIT’s Albert Dorman Honors College. He recieved an Edward F. Weston Medal for Professional Achievement and was inducted into the National Academy of Engineering in 2019.